Broadbent’s background includes more than 10 years of corporate finance experience at prominent Wall Street investment banks, including Salomon Brothers and PaineWebber Incorporated, where she advised clients primarily in the area of mergers and acquisitions.
Concurrently with the appointment of Broadbent, Albert J. Pavucek will be appointed Principal Financial Consultant of Orthovita.
“We are very pleased to welcome Nancy to Orthovita,” said Antony Koblish, president and chief executive officer. “With several years of strong historical sales growth for our existing products and a regulatory submission for our CORTOSS product candidate under review by the FDA, Orthovita is at an exciting stage of its development. Nancy’s 25 years of financial experience, including 15 years as the chief financial officer of several emerging growth companies in the healthcare industry, will be an important asset as we continue our efforts to build and expand our orthobiologics and biosurgery businesses.”
